Compounds that inhibit MCL-1 protein
US12024529B2 · kind B2 · utility
0Cited by
5References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 8, 2023 |
| Grant date | Jul 2, 2024 |
| Priority date | — |
| Expiry date | May 8, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.